aTyr Pharma, Inc.(US:ATYR) Globenewswireยท2025-10-13 20:00Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the efficacy of its drug Efzofitimod, which led to a significant drop in stock price after disappointing study results were announced [3][4]. Summary by Sections Allegations - The complaint alleges that aTyr Pharma made overwhelmingly positive statements about Efzofitimod while concealing material adverse facts about the drug's efficacy, particularly its ability to allow patients to taper steroid usage completely [3]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically regarding the change from baseline in mean daily OSC dose at week 48 [3]. Stock Price Impact - Following the announcement of the study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [3]. Class Action Details - Shareholders who purchased shares of aTyr during the class period from January 16, 2025, to September 12, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 8, 2025 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Law Firm Information - The Gross Law Firm, a nationally recognized class action law firm, is representing the shareholders and aims to protect investors' rights against deceit and fraud [5].